Zinc L-carnosine complex polaprezinc for pica and polydipsia

Zinc L-carnosine complex polaprezinc for pica and polydipsia - Zinc L-carnosine complex polaprezinc for pica and polydipsia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016738

Enrollment

Registered

2015-03-08

Start date

2015-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pica and polydipsia

Interventions

Polaprezinc 75 or 150 mg/day per os for 24 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) At least 20 years of age 2) Pica for 1 month or more according to DSM-V 3) Written informed consent from patients and their legal guardians prior to study entry

Exclusion criteria

Exclusion criteria: 1) Malignant tumor 2) Chronic renal failure (estimated glomerular filtration rate, eGFR <45) 3) Other severe diseases 4) Terminal phase of an illness 5) History of taking polaprezinc or other zinc supplementation

Design outcomes

Primary

Measure	Time frame
Frequency of pica	—

Secondary

Measure	Time frame
Severity of polydipsia assessed by diurnal weight gain and blood concentration of sodium Serum concentrations of BDNF and mature BDNF	—

Countries

Japan

Contacts

Public ContactKensaku Sakae

Keieikai Yashio Hospital Department of psychiatry

yashiohp@nifty.com048-996-3034

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026